China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced on Dec 4th that the Company’s Chief Financial Officer, Mr. Frank Waung, is scheduled to present at the CLSA Emerging Markets Pharma Conference in New York.
 
Mr. Waung will be available to meet with investors throughout the conference. Please contact your respective institutional sales representative for further details.
About China Pharma Holdings, Inc.
 
China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures, and markets treatments for a wide range of high incidence and high mortality conditions in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective, high margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding distribution network across 30 provinces, municipalities and autonomous regions. The Company is registered in Delaware, USA. Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson), located in Haikou City, Hainan Province, China, is a wholly owned subsidiary of China Pharma Holdings, Inc. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com.
 
 
Editorial Message  
This site contains materials from other clearly stated media sources for the purpose of discussion stimulation and content enrichment among our members only.
whatsonsanya.com does not necessarily endorse their views or the accuracy of their content. For copyright infringement issues please contact
editor@whatsonsanya.com